International Journal of Infectious Diseases (Feb 2024)
Detection of SARS-CoV-2 BA.2.86 by lateral flow devices
- Abbie Bown,
- Angela Sweed,
- Matthew Catton,
- Joshua Nelthorpe-Cowne,
- Hermione Conti-Frith,
- Ruth Elderfield,
- Jacob Terrey,
- Hamsa Abib,
- Caleb Lui,
- Ella Fisher,
- Kevin R. Bewley,
- Naomi S. Coombes,
- Donna Robinson,
- Somya Agrawal,
- Bassam Hallis,
- Edward Blandford,
- Tom Fowler,
- Deborah A. Williamson,
- Richard Vipond
Affiliations
- Abbie Bown
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK; Corresponding author:
- Angela Sweed
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Matthew Catton
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Joshua Nelthorpe-Cowne
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Hermione Conti-Frith
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Ruth Elderfield
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Jacob Terrey
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Hamsa Abib
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Caleb Lui
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Ella Fisher
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Kevin R. Bewley
- Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK
- Naomi S. Coombes
- Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK
- Donna Robinson
- Product and Delivery, UK Health Security Agency, UK
- Somya Agrawal
- Product and Delivery, UK Health Security Agency, UK
- Bassam Hallis
- Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK
- Edward Blandford
- Public Health and Clinical Oversight, Clinical and Public Health Division, UK Health Security Agency, UK
- Tom Fowler
- Public Health and Clinical Oversight, Clinical and Public Health Division, UK Health Security Agency, UK
- Deborah A. Williamson
- Specialist Microbiology and Laboratories, UK Health Security Agency, UK
- Richard Vipond
- Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK
- Journal volume & issue
-
Vol. 139
pp. 168 – 170
Abstract
We evaluated the performance of 12 lateral flow devices by assessing their analytical sensitivity for SARS-CoV-2 variant BA.2.86. Kits from ACON, Orient Gene, Xiamen Biotime, Getein, and SureScreen detected variant BA.2.86 to sufficient sensitivity levels, comparable to those observed with previous Omicron variants. The stocks of lateral flow devices currently held by the UK government do not currently need changing for deployment for this variant.
